Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
SVRA Savara Inc
- Stocks
- Healthcare
- NASDAQ: SVRA
Price (delayed)
$3.07
Market cap
$530.61M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.48
Enterprise value
$540.58M
Savara is an orphan lung disease company. Its lead program, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Its management
Highlights
SVRA's quick ratio is up by 9% from the previous quarter
Savara's equity has increased by 21% YoY but it has decreased by 14% from the previous quarter
SVRA's net income has plunged by 58% YoY and by 7% from the previous quarter
The company's EPS fell by 33% YoY
Key stats
What are the main financial stats of SVRA
Market
Valuations
Earnings
Shares outstanding
172.84M
Market cap
$530.61M
Enterprise value
$540.58M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.58
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$109.16M
Net income
-$102.17M
EBIT
-$102.17M
EBITDA
-$101.9M
Free cash flow
-$95.65M
Per share
Balance sheet
Liquidity
EPS
-$0.48
EPS diluted
-$0.48
Free cash flow per share
-$0.44
Book value per share
$0.86
Revenue per share
$0
TBVPS
$0.88
Total assets
$189.32M
Total liabilities
$41.47M
Debt
$29.52M
Equity
$147.85M
Working capital
$165.55M
Debt to equity
0.2
Current ratio
14.91
Quick ratio
14.5
Net debt/EBITDA
-0.1
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-52.4%
Return on equity
-65.9%
Return on invested capital
-53.8%
Return on capital employed
-57.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SVRA stock price
How has the Savara stock price performed over time
Intraday
-1.29%
1 week
7.34%
1 month
4.78%
1 year
-34.96%
YTD
0%
QTD
10.83%
Financial performance
How have Savara's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$109.16M
Net income
-$102.17M
Gross margin
N/A
Net margin
N/A
SVRA's net income has plunged by 58% YoY and by 7% from the previous quarter
Savara's operating income has plunged by 55% YoY and by 6% from the previous quarter
Price vs fundamentals
How does SVRA's price correlate with its fundamentals
Growth
What is Savara's growth rate over time
Valuation
What is Savara stock price valuation
P/E
N/A
P/B
3.58
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS fell by 33% YoY
The stock's price to book (P/B) is 49% more than its 5-year quarterly average of 2.4 but 6% less than its last 4 quarters average of 3.8
Savara's equity has increased by 21% YoY but it has decreased by 14% from the previous quarter
Efficiency
How efficient is Savara business performance
SVRA's return on assets is down by 30% year-on-year and by 2.3% since the previous quarter
Savara's ROIC has decreased by 28% YoY and by 2.5% from the previous quarter
SVRA's ROE is down by 27% YoY and by 2.2% from the previous quarter
Dividends
What is SVRA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SVRA.
Financial health
How did Savara financials performed over time
The total assets has grown by 20% YoY but it has contracted by 11% from the previous quarter
SVRA's total liabilities is up by 14% year-on-year
The debt is 80% smaller than the equity
The debt to equity has grown by 25% from the previous quarter but it has contracted by 9% YoY
Savara's equity has increased by 21% YoY but it has decreased by 14% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.